Daniel Joseph OConnell
Known title: President and CEOCIK: 0001865136
Associated companies
Transaction History
| ABOS | ▼ Sell | Open Market | 2,689 | $5K | 1/22/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 9,346 | $17K | 1/21/2026 | View on chart |
| ABOS | ▲ Buy | Grant | 299,800 | $0 | 1/20/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 5,388 | $9K | 1/12/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 12,941 | $23K | 1/9/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 8,143 | $15K | 1/8/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 37,755 | $75K | 1/7/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 5,102 | $10K | 1/6/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 4,649 | $9K | 1/5/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 12,619 | $20K | 1/21/2025 | View on chart |
| ABOS | ▲ Buy | Grant | 225,400 | $0 | 1/7/2025 | View on chart |
| ABOS | ▼ Sell | Open Market | 47,778 | $88K | 1/3/2025 | View on chart |
| ABOS | ▼ Sell | Open Market | 15,200 | $53K | 1/19/2024 | View on chart |
| ABOS | ▲ Buy | Grant | 401,000 | $0 | 1/2/2024 | View on chart |
| ABOS | ▲ Buy | Grant | 114,000 | $0 | 1/17/2023 | View on chart |
| ABOS | ▲ Buy | Option Exercise | 1,118 | $5K | 11/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Acumen Pharmaceuticals Featured in Alzheimer's Day Stock List
Acumen Pharmaceuticals was included in a Yahoo Finance article highlighting four Alzheimer's drug stocks to watch on World Alzheimer's Day. The mention serves as a reminder of the company's focus on neurodegenerative diseases, though the article does not report any new clinical data or corporate announcements. The stock is currently trading near its 52-week low, with an average analyst target of $7.60.
Acumen Pharmaceuticals Featured in Alzheimer's Day Stock List. Acumen Pharmaceuticals was included in a Yahoo Finance article highlighting four Alzheimer's drug stocks to watch on World Alzheimer's Day. The mention serves as a reminder of the company's focus on neurodegenerative diseases, though the article does not report any new clinical data or corporate announcements. The stock is currently trading near its 52-week low, with an average analyst target of $7.60.